Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease

2021 ◽  
Author(s):  
Jia‐Li Pu ◽  
Chong‐Yao Jin ◽  
Zhong‐Xuan Wang ◽  
Yi Fang ◽  
Yao‐Lin Li ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Apolipoprotein E Genotype

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson’s Disease

2009 ◽  
Vol 256 (3) ◽  
pp. 493-498 ◽  
Author(s):  
C. H. Williams-Gray ◽  
A. Goris ◽  
M. Saiki ◽  
T. Foltynie ◽  
D. A. S. Compston ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Risk Factor ◽  
Apolipoprotein E ◽  
Apolipoprotein E Genotype

Increased susceptibility to sporadic Parkinson's disease by a certain combined ?-synuclein/apolipoprotein E genotype

1999 ◽  
Vol 45 (5) ◽  
pp. 611-617 ◽  
Author(s):  
Rejko Kr�ger ◽  
Ana Maria Menezes Vieira-Saecker ◽  
Wilfried Kuhn ◽  
Daniela Berg ◽  
Thomas M�ller ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Sporadic Parkinson’S Disease ◽  
Apolipoprotein E Genotype ◽  
Increased Susceptibility

Apolipoprotein E genotype in Spanish patients of Alzheimer's or Parkinson's disease

1995 ◽  
Vol 134 (1-2) ◽  
pp. 146-149 ◽  
Author(s):  
Dolores Ibarreta ◽  
Teresa Gómez-Isla ◽  
Alberto Portera-Sánchez ◽  
Roberto Parrilla ◽  
Matilde S. Ayuso
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Apolipoprotein E Genotype

Alzheimer's disease with and without coexisting Parkinson's disease changes: Apolipoprotein E genotype and neuropathologic correlates

Neurology ◽  
1995 ◽  
Vol 45 (11) ◽  
pp. 1985-1990 ◽  
Author(s):  
M. Gearing ◽  
J. A. Schneider ◽  
G. W. Rebeck ◽  
B. T. Hyman ◽  
S. S. Mirra
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Apolipoprotein E Genotype

Modulation of disease risk according to a cathepsin D / apolipoprotein E genotype in Parkinson's disease

2003 ◽  
Vol 110 (7) ◽  
pp. 749-755 ◽  
Author(s):  
T. Schulte ◽  
S. Böhringer ◽  
L. Schöls ◽  
T. Müller ◽  
C. Fischer ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Cathepsin D ◽  
Disease Risk ◽  
Apolipoprotein E Genotype

Impact of the apolipoprotein E ε4 allele on early Parkinson's disease progression

2021 ◽  
Vol 83 ◽  
pp. 66-70
Author(s):  
Ryul Kim ◽  
Sangmin Park ◽  
Dallah Yoo ◽  
Jin-Sun Jun ◽  
Beomseok Jeon
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Disease Progression ◽  
Ε4 Allele ◽  
Early Parkinson’S Disease

scholarly journals Evaluation of Serum Apolipoprotein E as a Potential Biomarker for Pharmacological Therapeutic Efficacy Monitoring in Dopamine Dictated Disease Spectrum of Schizophrenia and Parkinson’s disease: A Preliminary Study

2018 ◽  
Vol 10 ◽  
pp. 117957351880358 ◽  
Author(s):  
Ashish Kumar Gupta ◽  
Komal Rani ◽  
Surabhi Swarnkar ◽  
Gaurav Khunger Kumar ◽  
Mohd Imran Khan ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Pharmacological Intervention ◽  
Enzyme Linked Immunosorbent Assay ◽  
Disease States ◽  
Disease Spectrum ◽  
Potential Biomarker ◽  
Schizophrenic Patients ◽  
The Right

Aim of the Study: Parkinson’s disease and schizophrenia are disease end points of dopaminergic deficit and hyperactivity, respectively, in the mid brain. Accordingly, current medications aim to restore normal dopamine levels, overshooting of which results in adverse effects of psychosis and extra-pyramidal symptoms, respectively. There are currently no available laboratory tests to guide treatment decisions or help predict adverse side effects of the drugs. The aim was to therefore explore the possibility of using apolipoprotein E as a biomarker to monitor pharmacological intervention in dopamine dictated states of Parkinson’s disease and schizophrenia for optimum therapy. Methods: Naïve and treated, Parkinson’s disease and schizophrenic patients were recruited from neurology and psychiatry clinics. Serum of healthy volunteers was collected as controls. Serum concentrations of apolipoprotein E was estimated by enzyme-linked immunosorbent assay (ELISA). Pathway analysis was carried out to delineate the interactions of apolipoprotein E in Parkinson’s disease and schizophrenia. Results: Apolipoprotein E levels are higher in Parkinson’s disease patients as compared with schizophrenic samples ( P < .05). Also, post-treatment apolipoprotein E levels in both disease states were at par with levels seen in healthy controls. The interactions of apolipoprotein E validate the results and place the differential expression of the protein in Parkinson’s disease and schizophrenia in the right perspective. Conclusion: Apolipoprotein E concentration across the dopaminergic spectrum suggests that it can be pursued not only as a potential biomarker in schizophrenia and Parkinson’s disease, but can also be an effective tool for clinicians to determine efficacy of drug-based therapy.

Apolipoprotein E ɛ4 allele in familial and sporadic Parkinson's disease

2006 ◽  
Vol 406 (3) ◽  
pp. 235-239 ◽  
Author(s):  
L. Blázquez ◽  
D. Otaegui ◽  
A. Sáenz ◽  
C. Paisán-Ruiz ◽  
J.I. Emparanza ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Apolipoprotein E ◽  
Sporadic Parkinson’S Disease ◽  
E4 Allele
Sign in / Sign up

Export Citation Format

Share Document